anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Brainstorm Cell Therapeutics · conference-presentation

BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides

15 pages · 4 arc beats · 2 loops

Conference-Presentation Download JSON
Unlock

BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides

Brainstorm Cell Therapeutics · 2022-10
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 19 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 3 slides 100% 3/3 slides 100% 3/3 slides · 15 hits
— 0/3 slides
33.3% 1/3 slides 66.7% 2/3 slides 100% 3/3 slides 66.7% 2/3 slides · 3 hits Agitate 2 slides 100% 2/2 slides 100% 2/2 slides · 9 hits
— 0/2 slides
— 0/2 slides
50% 1/2 slides 100% 2/2 slides 100% 2/2 slides · 4 hits Solution 9 slides 100% 9/9 slides 100% 9/9 slides · 51 hits
— 0/9 slides
11.1% 1/9 slides 33.3% 3/9 slides 100% 9/9 slides · 14 hits 55.6% 5/9 slides Key Takeaways 5 slides 100% 5/5 slides 100% 5/5 slides · 28 hits
— 0/5 slides
20% 1/5 slides 40% 2/5 slides 100% 5/5 slides · 10 hits 40% 2/5 slides

Slide inventory

15
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detailBeat · Problem
02
The chart is a dot plot comparing baseline ALSFRS-R scores across various clinical trials, highlighting NurOwn's lower baseline.preempt_rebuttal
Open slide detailBeat · ProblemLoop · Cost Of Inaction
03
The slide highlights a subgroup analysis where the treatment effect becomes statistically significant (p=0.050) in the secondary endpoint.analyze_data
Open slide detailBeat · ProblemLoop · Before After
04
establish_context
Open slide detailBeat · AgitateLoop · Before After
05
The slide uses a timeline-based process diagram to explain the clinical trial structure.present_framework
Open slide detailBeat · AgitateLoop · Before After
06
Mentions specific statistical models: PCA, MMRM, and mixed stepwise regression.present_framework
Open slide detailBeat · SolutionLoop · Before After
07
The slide outlines the primary endpoint (Clinical Response) and a secondary/supporting metric (piecewise slope) for ALS clinical trials.present_framework
Open slide detailBeat · SolutionLoop · Before After
08
The slide details the specific biomarkers used in the study and the exclusion criteria based on missing data.analyze_data
Open slide detailBeat · SolutionLoop · Before After
09
The chart displays the first principal component for each pathway over 20 weeks, comparing NurOwn and Placebo groups.analyze_data
Open slide detailBeat · SolutionLoop · Before After
10
The slide uses a consistent color scheme (blue for NurOwn, red for Placebo) and indicates statistical significance with asterisks.analyze_data
Open slide detailBeat · SolutionLoop · Before After
11
The slide uses line charts with error bars to compare treatment effects across two subgroups (<=25 and >25 baseline ALSFRS-R).analyze_data
Open slide detailBeat · Solution
12
The slide uses four line charts to demonstrate treatment effects on biomarkers, showing statistical significance markers.analyze_data
Open slide detailBeat · Solution
13
The slide uses color-coding to link specific biomarkers to biological pathways.summarize
Open slide detailBeat · Solution
14
summarize
Open slide detailBeat · Solution
15
The slide uses a logo-grid layout to establish credibility and network scope.establish_context
Open slide detail